PT3848372T - Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections - Google Patents
Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infectionsInfo
- Publication number
- PT3848372T PT3848372T PT202103297T PT20210329T PT3848372T PT 3848372 T PT3848372 T PT 3848372T PT 202103297 T PT202103297 T PT 202103297T PT 20210329 T PT20210329 T PT 20210329T PT 3848372 T PT3848372 T PT 3848372T
- Authority
- PT
- Portugal
- Prior art keywords
- compounds useful
- fused tricyclic
- pyridazinone compounds
- treat
- orthomyxovirus infections
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3848372T true PT3848372T (en) | 2024-03-22 |
Family
ID=59923494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177715877T PT3504214T (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| PT202103297T PT3848372T (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177715877T PT3504214T (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10160764B2 (en) |
| EP (3) | EP3504214B1 (en) |
| JP (2) | JP7221861B2 (en) |
| CN (2) | CN109863151B (en) |
| AR (1) | AR109438A1 (en) |
| CA (1) | CA3035302A1 (en) |
| ES (1) | ES2859510T3 (en) |
| JO (1) | JOP20170169A1 (en) |
| MX (1) | MX2019002438A (en) |
| PL (2) | PL3504214T3 (en) |
| PT (2) | PT3504214T (en) |
| SI (2) | SI3504214T1 (en) |
| TW (2) | TWI803467B (en) |
| UY (1) | UY37378A (en) |
| WO (1) | WO2018042303A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160661A1 (en) * | 2013-09-12 | 2016-08-05 | Alios Biopharma Inc | AZAPIRIDONE COMPOUND AND ITS USES THEREOF |
| SG11201804348SA (en) | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| US10858366B2 (en) | 2016-03-08 | 2020-12-08 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| CN110494141A (en) | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | Pharmaceutical composition containing substituted polycyclic Pyridione derivatives and its prodrug |
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| SG11202011447UA (en) | 2018-01-17 | 2020-12-30 | Jiangxi Caishi Pharmaceutical Technology Co Ltd | Pyridone derivative, composition and use as antiviral drug thereof |
| CR20200372A (en) * | 2018-02-28 | 2020-10-26 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| CN108440564B (en) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | Substituted polycyclic carbamoylpyridone derivative and its prodrug |
| CN113195502A (en) * | 2018-10-10 | 2021-07-30 | 詹森生物制药有限公司 | Macrocyclic influenza endonuclease inhibitors |
| CN115135646B (en) * | 2019-12-23 | 2024-05-17 | 石家庄迪斯凯威医药科技有限公司 | Substituted polycyclic compounds, pharmaceutical compositions and uses thereof |
| WO2022105669A1 (en) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | Se-se-containing macrocyclic compound |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| CN101513402B (en) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | Antiviral agent |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| FR2901795A1 (en) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | DERIVATIVES OF PYRIMIDINO [1 ', 6'-1,2] PYRIDO [3,4-B] INDOLES AND THEIR USE IN THERAPEUTICS |
| JP5498393B2 (en) | 2008-10-31 | 2014-05-21 | 塩野義製薬株式会社 | Cephalosporins with catechol groups |
| TWI518084B (en) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| PT2444400T (en) | 2009-06-15 | 2018-06-06 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative |
| US8445503B2 (en) | 2009-12-23 | 2013-05-21 | Elan Pharmaceuticals, Inc. | Inhibitors of polo-like kinase |
| US8541407B2 (en) | 2010-03-31 | 2013-09-24 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| SI2620436T1 (en) | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
| EP2889287B1 (en) | 2012-09-20 | 2016-08-31 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same |
| CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| BR112016003348B1 (en) | 2013-08-21 | 2023-03-07 | Alios Biopharma, Inc | ANTIVIRAL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITION AND THEIR USES |
| EP3043806A4 (en) | 2013-09-11 | 2017-05-17 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| DK3030549T3 (en) | 2013-09-12 | 2019-05-13 | Janssen Biopharma Inc | PYRIDAZINON COMPOUNDS AND USES THEREOF |
| PE20160661A1 (en) * | 2013-09-12 | 2016-08-05 | Alios Biopharma Inc | AZAPIRIDONE COMPOUND AND ITS USES THEREOF |
| CN107074880A (en) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | The diketone of dihydro pyrido pyrazine 1,8 and their purposes in treating, ameliorating or preventing virus disease |
| EP3268368A4 (en) | 2015-03-11 | 2018-11-14 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| US10858366B2 (en) | 2016-03-08 | 2020-12-08 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| US10183945B2 (en) | 2016-03-10 | 2019-01-22 | Alios Biopharma, Inc. | Method of preparing AZA-pyridone compounds |
| MX2019000200A (en) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Pyrimidine-based antiproliferative agents. |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CN110494141A (en) | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | Pharmaceutical composition containing substituted polycyclic Pyridione derivatives and its prodrug |
| JOP20170169A1 (en) * | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| JP2019059697A (en) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | Substituted polycyclic pyridazine derivatives and prodrugs thereof |
| CN110041327B (en) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament |
| SG11202011447UA (en) | 2018-01-17 | 2020-12-30 | Jiangxi Caishi Pharmaceutical Technology Co Ltd | Pyridone derivative, composition and use as antiviral drug thereof |
| AR123121A1 (en) | 2018-02-28 | 2022-11-02 | Japan Tobacco Inc | DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS FUSIONED WITH SATURATED RING AND THEIR PHARMACEUTICAL USE |
| AR114270A1 (en) | 2018-02-28 | 2020-08-12 | Japan Tobacco Inc | 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| CN111801100B (en) | 2018-02-28 | 2023-10-24 | 豪夫迈·罗氏有限公司 | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer |
| CR20200372A (en) | 2018-02-28 | 2020-10-26 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
-
2016
- 2016-08-29 JO JOP/2017/0169A patent/JOP20170169A1/en unknown
-
2017
- 2017-08-25 ES ES17771587T patent/ES2859510T3/en active Active
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 PT PT177715877T patent/PT3504214T/en unknown
- 2017-08-25 MX MX2019002438A patent/MX2019002438A/en unknown
- 2017-08-25 PL PL17771587T patent/PL3504214T3/en unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/en active Active
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/en active Active
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en unknown
- 2017-08-25 EP EP23217305.4A patent/EP4356969A3/en active Pending
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/en unknown
- 2017-08-25 SI SI201730650T patent/SI3504214T1/en unknown
- 2017-08-25 PT PT202103297T patent/PT3848372T/en unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614A/en active Pending
- 2017-08-25 SI SI201731493T patent/SI3848372T1/en unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/en active
- 2017-08-28 UY UY0001037378A patent/UY37378A/en unknown
- 2017-08-28 TW TW112101158A patent/TW202342482A/en unknown
- 2017-08-29 AR ARP170102385A patent/AR109438A1/en unknown
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3848372T3 (en) | 2024-04-22 |
| US20220041610A1 (en) | 2022-02-10 |
| AR109438A1 (en) | 2018-11-28 |
| EP4356969A2 (en) | 2024-04-24 |
| CA3035302A1 (en) | 2018-03-08 |
| JOP20170169A1 (en) | 2019-01-30 |
| CN109863151A (en) | 2019-06-07 |
| US11912715B2 (en) | 2024-02-27 |
| EP4356969A3 (en) | 2024-05-22 |
| JP7221861B2 (en) | 2023-02-14 |
| US20200123167A1 (en) | 2020-04-23 |
| EP3504214A1 (en) | 2019-07-03 |
| EP3848372A1 (en) | 2021-07-14 |
| US10160764B2 (en) | 2018-12-25 |
| SI3504214T1 (en) | 2021-04-30 |
| TWI803467B (en) | 2023-06-01 |
| TW202342482A (en) | 2023-11-01 |
| PL3504214T3 (en) | 2021-07-19 |
| TW201811800A (en) | 2018-04-01 |
| WO2018042303A1 (en) | 2018-03-08 |
| EP3504214B1 (en) | 2020-12-02 |
| PT3504214T (en) | 2021-03-04 |
| SI3848372T1 (en) | 2024-04-30 |
| EP3848372B1 (en) | 2023-12-20 |
| ES2859510T3 (en) | 2021-10-04 |
| US11098051B2 (en) | 2021-08-24 |
| UY37378A (en) | 2018-03-23 |
| JP2023027102A (en) | 2023-03-01 |
| JP2019532033A (en) | 2019-11-07 |
| MX2019002438A (en) | 2019-07-08 |
| CN109863151B (en) | 2021-09-10 |
| US20180057501A1 (en) | 2018-03-01 |
| CN113683614A (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3504214T3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| HK1244276A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| PL3178817T3 (en) | Amorphous form of tetracyclic compound | |
| EP3303341A4 (en) | Fused tricyclic heterocyclic compounds useful for treating hiv infection | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| IL254424A0 (en) | Substituted tricyclic heterocyclic compounds | |
| HK1251465A1 (en) | Compositions comprising tricyclic heterocyclic compounds | |
| PT3535257T (en) | Process for purification of pyrazolpyridazines | |
| SG11201702274RA (en) | Process for purification of organic composition | |
| IL249907A0 (en) | Tricyclic triazolic compounds | |
| IL260094A (en) | Treatment of hand eczema | |
| GB201409161D0 (en) | Routing scheme switching | |
| IL248838A0 (en) | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | |
| GB201404848D0 (en) | Pathogenic infections | |
| ZA201801775B (en) | Soap bar having separate concentrated regions of specifically selected components | |
| PL3494122T3 (en) | Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use | |
| ZA201700710B (en) | Pathogenic control of apoptosis | |
| PL3131890T3 (en) | Compounds for treating viral infections | |
| GB201510870D0 (en) | Treatment of infarction | |
| ZA201902183B (en) | Purification process of fviii | |
| ZA201804025B (en) | Inactivation of viruses by delipidation | |
| GB201619704D0 (en) | Treatment of pathogenic infections | |
| GB201512635D0 (en) | Uses of therapeutic compounds | |
| PL3137475T3 (en) | Purification of epidaunorubicin |